SummaryRMgm-156
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 18403203 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | P. berghei ANKA 2.34 |
Other information parent line | P. berghei ANKA 2.34 is a cloned, gametocyte producer line of the ANKA strain (PubMed: PMID: 15137943). |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | M. Hirai; H. Matsuoka |
Name Group/Department | Division of Medical Zoology, Department of Infection and Immunity |
Name Institute | Jichi Medical University School of Medicine |
City | Shimotsuke City |
Country | Japan |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-156 |
Principal name | PbGCS1(-) (clone 1-3; 2-5; 3-6) |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Normal numbers of male and female gametocytes are produced. Gamete formation was comparable to that of wild type parasites, as determined by light microscopy of exflagellation (male gamete formation) and escape of females from the host erythrocyte. Male gametes are sterile as shown by the lack of fertilisation when the mutant males are crossed with fertile female gametes. Mutant female gametes are fertile as shown by cross-fertilisation with wild type male gametes. |
Fertilization and ookinete | Gamete formation was comparable to that of wild type parasites, as determined by light microscopy of exflagellation (male gamete formation) and escape of females from the host erythrocyte. Male gametes are sterile as shown by the lack of fertilisation when the mutant males are crossed with fertile female gametes. Mutant female gametes are fertile as shown by cross-fertilisation with wild type male gametes. Mutant males gametes showed flagella motility and adhesion to surrounding erythrocytes, forming exfagellating centers comparable to wild type. However, no successful entering of flagella into female gametes was observed. |
Oocyst | No ookinete and oocyst formation (see phenotype 'Fertilization and ookinete'). |
Sporozoite | No sporozoite formation (see phenotype 'Fertilization and ookinete' and 'Oocyst'). |
Liver stage | Not different from wild type |
Additional remarks phenotype | Mutant/mutation Additional information |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1212600 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1014200 | ||||||||||||||||||||||||
Gene product | male gamete fusion factor HAP2, putative | ||||||||||||||||||||||||
Gene product: Alternative name | HAP2; GCS1, Generative Cell Specific 1 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | Plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Partial | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | Part of the 5' and 3' pbgcs1 coding region was used as targetting sequences. | ||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | |||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
![]() Primer information: Primers used for amplification of the target sequences
![]()
| |||||||||||||||||||||||||
top of page |